CERPASSRX CONTINUES TO DELIVER VALUE BY ADDING SIMLANDI TO ITS FORMULARY AT PARITY WITH HUMIRA
CerpassRx is excited to announce a significant update to our formulary with the addition of Simlandi, a citrate-free, high-concentration, interchangeable biosimilar to Humira, as a preferred alternative effective June 1, 2024.
Biosimilars are FDA-approved copies of complex biologic drugs that have been shown to be highly similar to the originator product in terms of safety, efficacy and quality. Our biosimilar strategy is designed to introduce meaningful choices and significant savings opportunities. By offering Simlandi at parity with Humira, we provide a valuable alternative that supports both financial efficiency and high-quality care. The increased competition among Humira biosimilars is anticipated to bring down overall costs, making advanced treatments more accessible to our members.
ABOUT SIMLANDI
Simlandi is an FDA-approved biosimilar for Humira, designed to treat multiple chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease. It is formulated as a high-concentration, citrate-free solution, which enhances patient comfort by reducing injection site pain. The interchangeability status of Simlandi means that, where permitted by state law, pharmacies can substitute Simlandi for Humira without the need for prescriber consultation, similar to how generic drugs are substituted for brand-name medications.
SIMLANDI FORMULARY BENEFITS
The addition of Simlandi to our formulary represents a strategic move to enhance the range of treatment options available to our members. Simlandi’s introduction is expected to drive significant cost savings without compromising clinical outcomes. The comprehensive evaluation process for Simlandi included assessments of clinical appropriateness, supply chain integrity, interchangeability, formulation, and potential savings opportunities. This helps to ensure that Simlandi meets our high standards for safety, efficacy, and reliability.
HUMIRA FORMULARY ALTERNATIVES
As of June 1, 2024, the preferred formulary alternatives for Humira will include Simlandi, alongside other notable biosimilars such as Cyltezo, Adalimumab-adbm, Hyrimoz (only Hyrimoz NDCs starting with 61314), and Adalimumab-adaz. Notably, Humira will continue to be available, but only specific NDCs starting with 00074 will be included.
NEXT STEPS
We encourage you to engage actively with your Partner Relations team to help address any questions or concerns and facilitate a smooth transition. Any deviations from the recommended formulary updates should be communicated to CerpassRx for further review and guidance. We remain dedicated to closely monitoring the market and will provide ongoing updates as additional Humira biosimilars are approved.
###
About CerpassRx
CerpassRx, a leading full-service PBM, is renowned for its tailored solutions addressing diverse client needs. Its distinctive approach encompasses prescription optimization programs, flexible formulary designs, personalized member services, and efficient mail delivery and specialty pharmacy programs. Integrating top-tier pharmacy tools and expertise with premier PBM services, CerpassRx exemplifies excellence. Central to its core values are collaboration, accountability, passion, and empowerment. By prioritizing these principles, CerpassRx empowers clients, fostering an alliance built on trust and mutual success. The company’s mission is clear: to redefine standards and push boundaries, ultimately driving positive change and heightened efficiency in pharmacy benefit management.